Protara Therapeutics, Inc.
TARA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001359931
No open-market purchases or sales by Protara Therapeutics, Inc. insiders were filed in the last 90 days; 119 institutions reported holding it in 13F filings for Q2 2026, worth $176.0M in total; no superinvestor holds it.
13F holders, Q3 2021
Institutional positions in Protara Therapeutics, Inc. as of Sep 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 36
- −4 vs. Q2 2021
- Shares held
- 6.31M
- −799.0K (−11.2%) vs. Q2 2021
- Total value
- $43.7M
- −$25.6M (−36.9%) vs. Q2 2021
- New holders
- 7
- 11 more added
- Sold out
- 11
- 10 more reduced
Compare with Q2 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TARA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 119 | $176.0M |
| Q1 2026 | 114 | $237.4M |
| Q4 2025 | 105 | $212.3M |
| Q3 2025 | 81 | $114.0M |
| Q2 2025 | 76 | $90.1M |
| Q1 2025 | 59 | $123.8M |
| Q4 2024 | 60 | $156.6M |
| Q3 2024 | 35 | $19.1M |
| Q2 2024 | 38 | $22.2M |
| Q1 2024 | 34 | $18.3M |
| Q4 2023 | 30 | $8.17M |
| Q3 2023 | 31 | $8.55M |
| Q2 2023 | 29 | $12.3M |
| Q1 2023 | 29 | $16.9M |
| Q4 2022 | 30 | $14.7M |
| Q3 2022 | 31 | $16.7M |
| Q2 2022 | 33 | $18.4M |
| Q1 2022 | 35 | $33.2M |
| Q4 2021 | 38 | $46.5M |
| Q3 2021 | 36 | $43.7M |
| Q2 2021 | 40 | $69.3M |
| Q1 2021 | 50 | $134.0M |
Institutions, Q3 2021
Shares, value and share of portfolio for each institution holding Protara Therapeutics, Inc.; share changes are against Q2 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| American Portfolios Advisors | 100 | $692 | 0.00% | +100 | New |
| Bank of America Corp | 522 | $3.00K | 0.00% | −410−44.0% | Reduced |
| Wells Fargo & Company | 560 | $3.00K | 0.00% | +1+0.2% | Added |
| Royal Bank of Canada | 664 | $4.00K | 0.00% | +664 | New |
| Simplex Trading, LLC | 581 | $5.00K | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 2,600 | $18.0K | 0.00% | +2,600 | New |
| JPMorgan Chase & Co | 8,040 | $56.0K | 0.00% | +7,863+4,442.4% | Added |
| Trexquant Investment LP | 12,454 | $86.0K | 0.01% | +12,454 | New |
| Prelude Capital Management, LLC | 13,155 | $91.0K | 0.00% | +1,455+12.4% | Added |
| Jump Financial, LLC | 14,500 | $100.0K | 0.01% | +14,500 | New |
| Marshall Wace, LLP | 15,190 | $105.0K | 0.00% | −2,279−13.0% | Reduced |
| Susquehanna International Group, LLP | 15,893 | $110.0K | 0.00% | −4,716−22.9% | Reduced |
| Virtu Financial LLC | 17,130 | $119.0K | 0.01% | +17,130 | New |
| Bank of New York Mellon Corp | 17,907 | $124.0K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 22,279 | $154.0K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 22,800 | $158.0K | 0.00% | +12,441+120.1% | Added |
| Schonfeld Strategic Advisors LLC | 23,955 | $166.0K | 0.00% | −500−2.0% | Reduced |
| Morgan Stanley | 26,582 | $184.0K | 0.00% | −22,302−45.6% | Reduced |
| Knott David M | 36,479 | $252.0K | 0.11% | +315+0.9% | Added |
| BlackRock Inc. | 44,036 | $306.0K | 0.00% | +3,911+9.7% | Added |
| Boothbay Fund Management, LLC | 47,423 | $328.0K | 0.01% | −9,460−16.6% | Reduced |
| Geode Capital Management, LLC | 79,017 | $546.0K | 0.00% | −3,968−4.8% | Reduced |
| Millennium Management LLC | 104,918 | $726.0K | 0.00% | −24,462−18.9% | Reduced |
| Bridgeway Capital Management, LLC | 112,500 | $779.0K | 0.01% | +112,500 | New |
| Renaissance Technologies LLC | 115,900 | $802.0K | 0.00% | +64,473+125.4% | Added |
| Two Sigma Investments, LP | 130,935 | $906.0K | 0.00% | +75,530+136.3% | Added |
| Goldman Sachs Group Inc | 155,973 | $1.08M | 0.00% | +23,716+17.9% | Added |
| Two Sigma Advisers, LP | 168,818 | $1.17M | 0.00% | +110,500+189.5% | Added |
| Baker Bros. Advisors LP | 199,671 | $1.38M | 0.01% | 00.0% | Unchanged |
| Boxer Capital, LLC | 209,227 | $1.45M | 0.05% | 00.0% | Unchanged |
| Citadel Advisors LLC | 346,431 | $2.40M | 0.00% | +4,410+1.3% | Added |
| Perceptive Advisors LLC | 421,641 | $2.92M | 0.04% | 00.0% | Unchanged |
| Vanguard Group Inc | 435,813 | $3.02M | 0.00% | −1,295−0.3% | Reduced |
| OrbiMed Advisors LLC | 450,000 | $3.11M | 0.03% | 00.0% | Unchanged |
| Ikarian Capital, LLC | 479,995 | $3.32M | 0.76% | −104,809−17.9% | Reduced |
| Opaleye Management Inc. | 2,558,472 | $17.7M | 3.31% | 00.0% | Unchanged |
| Rock Springs Capital Management LP | 0 | $0 | 0.00% | −693,542−100.0% | Sold out |
| Franklin Resources Inc | 0 | $0 | 0.00% | −350,010−100.0% | Sold out |
| Ergoteles LLC | 0 | $0 | 0.00% | −17,700−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −13,678−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −12,151−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −1,548−100.0% | Sold out |
| Retirement Group, LLC | 0 | $0 | 0.00% | −500−100.0% | Sold out |
| Panagora Asset Management Inc | 0 | $0 | 0.00% | −55−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −99−100.0% | Sold out |
| New York State Common Retirement Fund | 0 | $0 | 0.00% | −29−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −15−100.0% | Sold out |